tiprankstipranks
Advertisement
Advertisement

AKTS Stock Latest News

Aktis Oncology price target raised to $35 from $33 at H.C. Wainwright
The FlyAktis Oncology price target raised to $35 from $33 at H.C. Wainwright
10d ago
AKTS
Early Clinical Data and Differentiated Miniprotein Platform Underpin Buy Rating on Aktis for B7-H3 Radiopharmaceutical in mCRPC
PremiumRatings
Early Clinical Data and Differentiated Miniprotein Platform Underpin Buy Rating on Aktis for B7-H3 Radiopharmaceutical in mCRPC
11d ago
AKTS
Analyst Reiterates Buy on Aktis Oncology, Maintains $34 Price Target Following Encouraging AKY-2519 ASCO Update
PremiumRatings
Analyst Reiterates Buy on Aktis Oncology, Maintains $34 Price Target Following Encouraging AKY-2519 ASCO Update
15d ago
AKTS
Aktis Oncology Initiated at Buy on Promising AKY-2519 Safety Profile and Broad B7‑H3 Radiopharma Market Opportunity
PremiumRatings
Aktis Oncology Initiated at Buy on Promising AKY-2519 Safety Profile and Broad B7‑H3 Radiopharma Market Opportunity
16d ago
AKTS
Aktis Oncology Initiated at Buy on Differentiated Radiopharmaceutical Platform and Multiple High-Value Oncology Targets
PremiumRatings
Aktis Oncology Initiated at Buy on Differentiated Radiopharmaceutical Platform and Multiple High-Value Oncology Targets
1M ago
AKTS
Aktis Oncology reports Q1 revenue $3.23M, consensus $1.85M
PremiumThe FlyAktis Oncology reports Q1 revenue $3.23M, consensus $1.85M
1M ago
AKTS
Aktis Oncology Initiated at Buy on Differentiated Radiopharmaceutical Platform and mCRPC Opportunity for AKY‑2519
Premium
Ratings
Aktis Oncology Initiated at Buy on Differentiated Radiopharmaceutical Platform and mCRPC Opportunity for AKY‑2519
1M ago
AKTS
Aktis Oncology initiates clinical trial of AKY-25191
Premium
The Fly
Aktis Oncology initiates clinical trial of AKY-25191
1M ago
AKTS
Aktis Oncology initiated with an Outperform at William Blair
PremiumThe Fly
Aktis Oncology initiated with an Outperform at William Blair
1M ago
AKTS
Aktis Oncology appoints Gormley as independent director of Board of Directors
PremiumThe Fly
Aktis Oncology appoints Gormley as independent director of Board of Directors
2M ago
AKTS
Aktis Oncology: Accelerated Pipeline Progress and High-Value Clinical Catalysts Underpin Buy Rating and $34 Target
PremiumRatings
Aktis Oncology: Accelerated Pipeline Progress and High-Value Clinical Catalysts Underpin Buy Rating and $34 Target
2M ago
AKTS
Aktis Oncology price target raised to $33 from $30 at H.C. Wainwright
PremiumThe Fly
Aktis Oncology price target raised to $33 from $30 at H.C. Wainwright
2M ago
AKTS
Aktis Oncology announces FDA clearance of AKY-25191 trial
PremiumThe FlyAktis Oncology announces FDA clearance of AKY-25191 trial
2M ago
AKTS
3 Best Stocks to Buy Today, 3/9/2026, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Today, 3/9/2026, According to Top Analysts
3M ago
MWH
AKTS
Aktis Oncology initiated with a Buy at H.C. Wainwright
Premium
The Fly
Aktis Oncology initiated with a Buy at H.C. Wainwright
3M ago
AKTS
Aktis Oncology’s NECTINIUM-2 Trial: A New Radiopharma Bet in Solid Tumors
PremiumCompany Announcements
Aktis Oncology’s NECTINIUM-2 Trial: A New Radiopharma Bet in Solid Tumors
3M ago
AKTS
Aktis Oncology: Fast-Track Momentum and Pipeline Catalysts Underpin Buy Rating and $34 Price Target
PremiumRatings
Aktis Oncology: Fast-Track Momentum and Pipeline Catalysts Underpin Buy Rating and $34 Price Target
4M ago
AKTS
Aktis Oncology receives U.S. FDA Fast Track Designation for AKY-1189
PremiumThe Fly
Aktis Oncology receives U.S. FDA Fast Track Designation for AKY-1189
4M ago
AKTS
Adobe downgraded, Palantir upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Adobe downgraded, Palantir upgraded: Wall Street’s top analyst calls
4M ago
V
MA
Aktis Oncology initiated with an Outperform at Leerink
PremiumThe FlyAktis Oncology initiated with an Outperform at Leerink
4M ago
AKTS
Aktis Oncology initiated with a Buy at BofA
Premium
The Fly
Aktis Oncology initiated with a Buy at BofA
4M ago
AKTS
Aktis Oncology: Differentiated Miniprotein Radiopharma Platform Underpins Buy Rating and Multi-Billion Dollar Sales Potential
Premium
Ratings
Aktis Oncology: Differentiated Miniprotein Radiopharma Platform Underpins Buy Rating and Multi-Billion Dollar Sales Potential
4M ago
AKTS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >